Hugel is taking its premium cosmetic brand BYRYZN BR to China, rolling out its first product in the market as part of a broader push into Asia’s high-end dermocosmetics sector.

The Korean medical aesthetics company said Monday that it has launched the BYRYZN BR Botuligin Capture EX Ampoule, a China-targeted version of its existing Botuligin Capture Ampoule, formulated to address wrinkles in three key zones: nasolabial folds, fine lines around the eyes, and forehead expression lines. 

Four additional products under the BYRYZN BR line -- focused on hydration, lipid barrier support, and skin elasticity -- are slated to follow in phases.

BYRYZN BR, introduced in Korea in April 2024, is powered by Hugel’s proprietary ingredients including TARGET HA, Botuligin, and H.ECM, and is designed to deliver anti-aging care across hydration, wrinkle reduction, and skin barrier reinforcement.

To support the launch, Hugel hosted an event at the InterContinental hotel in Hangzhou that drew roughly 250 attendees, including members of the China Anti-Aging Association, surgeons, and med-aesthetics specialists.

“With our entry into the Chinese market, BYRYZN BR marks a new global milestone following successful expansion into North America, Southeast Asia, and Northeast Asia,” a Hugel spokesperson said. “We aim to actively promote BYRYZN BR to meet the needs of China’s discerning dermocosmetic consumers.”